CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients With Advanced Gallbladder Carcinoma or Cholangiocarcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01093222
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:53.492124+00:00
Published At: 2014-01-29T00:00:00+00:00
Record Updated At: 2015-06-30
Results Posted At: 2014-01-29
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Extrahepatic Bile Duct Adenocarcinoma", "Gallbladder Adenocarcinoma", "Gallbladder Adenocarcinoma With Squamous Metaplasia", "Hilar Cholangiocarcinoma", "Recurrent Extrahepatic Bile Duct Carcinoma", "Recurrent Gallbladder Carcinoma", "Undifferentiated Gallbladder Carcinoma", "Unresectable Extrahepatic Bile Duct Carcinoma", "Unresectable Gallbladder Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2015-06-30"
protocolSection.identificationModule.nctId: "NCT01093222"
protocolSection.identificationModule.officialTitle: "Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients With Advanced Gallbladder Carcinoma or Cholangiocarcinoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2014-01-29"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.